Background: Myofascial Pain Dysfunction Syndrome is the most prevalent cause of orofacial pain and a subset of temporomandibular disorders. Treatment of MPDS necessitates deactivation of MTrPs, restoration of normal muscle length, and elimination or correction of the conditions that caused or perpetuated the TrPs in the first place. Our study aims to compare the efficacy of Botulinum Toxin type A therapy, Conservative therapy, and their combination in the management of MPDS Methods: Using simple random sampling with a random number generator, 15 patients diagnosed with MPDS were assigned to three groups. Group A received conservative treatment; group B received Botulinum Toxin A injection, and group C received both. The observations were based on pain assessment using Visual Analog Score, mouth opening in millimeters, and overall improvement.